Hemomitsin tab n / 500mg film about 3 pc

$6.39

Hemomitsin tab n / 500mg film about 3 pc

Quantity:

Description

Composition
Active substance:
1 tablet contains 500 mg azithromycin (azithromycin dihydrate form).
Excipients:
Silikatnaya microcrystalline cellulose – 69.00 mg, Microcrystalline Cellulose – 57.00 mg of sodium carboxymethyl starch (type A) – 46,00 mg Povidone – 24.00 mg, magniya stearat – 10.00 mg talc – 10.00 mg colloidal silicon dioxide – 1.00 mg; sheath: titanium dioxide – 10.58 mg talc – 9.57 mg, kopovidon – 4.95 mg, ethylcellulose – 4.95 mg, makrogol 6000 – 1.32 mg, indigo carmine (indigotin) E 132 – 1.22 mg , green dye lacquer 8% (indigo carmine (indigotin) E 132, quinoline yellow E 104) – 0.41 mg.
Description:
Round, biconvex tablets, film-coated grayish blue.
Product form:
Tablets, film-coated 500 mg.
3 tablets in blister AL / PVC. 1 blister with instructions for use in a cardboard pack.
Contraindications
Hypersensitivity (including to other macrolides…); liver and / or renal failure; Children up to age 12 years (for a given dosage form), lactation.
Precautions pregnancy, arrhythmia (ventricular fibrillation and lengthening the interval QT), children with severe liver or kidney function.
Precautions pregnancy, arrhythmia (ventricular fibrillation and lengthening the interval QT), children with severe liver or kidney function.
Dosage
500 mg
Indications
Infectious-inflammatory diseases caused by susceptible to malaria infections:
Infections of the upper respiratory tract and ENT (tonsillitis, sinusitis, tonsillitis, pharyngitis, otitis media);
Scarlet fever;
Infections of the lower respiratory tract (bacterial and atypical pneumonia, bronchitis);
skin and soft tissue infections (erysipelas, impetigo, secondarily infected dermatoses);
Urogenital tract infections (uncomplicated urethritis and / or cervicitis);
Lyme disease (Lyme disease), for the treatment of early stage (erythema migrans);
Disease stomach and duodenal ulcers, associated with Helicobacter Pylori (in combination therapy).
Interaction with other drugs
Antacids (aluminum and magnesium-containing), ethanol and food slow down and reduce the absorption.
When co-administration of warfarin and azithromycin (in normal doses) changes in prothrombin time were found, however, given that the interaction of macrolides and warfarin may be increased anticoagulant effect, patients requires careful monitoring of the prothrombin time.
Digoxin: increase of digoxin concentrations.
Ergotamine and dihydroergotamine: increased toxic effect (vasospasm, dysesthesia).
Triazolam: decrease in clearance and an increase in the pharmacological action of triazolam.
Slows down and increases the plasma concentration and toxicity of cycloserine, anticoagulants, methylprednisolone, felodipine, and PM, exposed to microsomal oxidation (carbamazepine, terfenadine, cyclosporine, hexobarbital, ergot alkaloids, valproate, disopyramide, bromocriptine, phenytoin, oral hypoglycemic agents, theophylline and other xanthine derivatives.) – due to the inhibition of microsomal oxidation in hepatocytes azithromycin.
Linkozaminy weaken the effectiveness of tetracycline and chloramphenicol – increase.
Pharmaceutical incompatible with heparin.
Overdose
Symptoms: severe nausea, temporary hearing loss, vomiting, diarrhea.
Treatment: symptomatic; gastric lavage.
pharmachologic effect
Pharmacological group:
Antibiotic azalide.
Pharmacological properties:
Broad-spectrum antibiotic. It is a representative subgroup of macrolide antibiotics – azalides. In high concentrations it has a bactericidal effect.
Azithromycin To a sensitive Gram-positive cocci: Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus Group C, F and G, Staphylococcus aureus,, Streptococcus viridans; Gram-negative bacteria: Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, Bordetella parapertussis, Legionella pneumophila, Haemophilus ducreyi, Campylobacter jejuni, Neisseria gonorrhoeae and Gardnerella vaginalis; Some anaerobic microorganisms: Bacteroides bivius, Clostridium perfringens, Peptostreptococcus spp; and Chlamydia trachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum, Treponema pallidum, Borrelia burgdoferi. Azithromycin is inactive against Gram-positive bacteria resistant to erythromycin.
Pharmacokinetics:
Azithromycin is rapidly absorbed from the gastrointestinal tract, due to its stability in an acidic medium and lipophilicity. After oral administration of 500 mg of azithromycin maximum concentration in plasma is achieved after 2.5 – 2.96 hr and 0.4 mg / l. Bioavailability is 37%.
Azithromycin well into the respiratory tract, organs and tissues of the urogenital tract (in particular in the prostate gland), in skin and soft tissue. The high concentration in tissues (10-50 times higher than in blood plasma) and a long half-life of azithromycin due to low binding to plasma proteins as well as its ability to penetrate into eukaryotic cells and concentrated in a low pH environment surrounding the lysosomes. This, in turn, defines a large apparent volume of distribution (31.1 l / kg) and high plasma clearance. The ability of azithromycin accumulate mainly in lysosomes is particularly important for the elimination of intracellular pathogens. It is shown that phagocytes deliver azithromycin localization of infection in places where it is released in the process of phagocytosis. The concentration of azithromycin in the foci of infection was significantly higher than in healthy tissue (on average 24-34%) and correlated with the degree of inflammatory edema. Despite the high concentration in phagocytes, azithromycin did not significantly affect their function. Azithromycin remains in bactericidal concentrations for 5-7 days after the last dose, which allowed the development of short (3-day and 5-day) courses of treatment.
In the liver demetiliruetsa formed metabolites are inactive.
Excretion of azithromycin from plasma takes place in 2 stages: half-life of 14-20 hours in the range of from 8 to 24 hours after drug administration and 41 hours – in the range from 24 to 72 hours, which allows the use of drug 1 time / day. Food intake was significantly alters the pharmacokinetics (depending upon the dosage form): Tablets – maximum concentration (Cmax) increased (31%), area under the curve (AUC) is not changed.
Pregnancy and breast-feeding
Application of pregnancy is possible only in those cases where the intended benefits to the mother outweighs the potential risk to the fetus.
If necessary, use during lactation should decide the issue of termination of breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
From the digestive system: diarrhea (5%), nausea (3%), abdominal pain (3%); 1% or less – dyspepsia, flatulence, vomiting, melena, cholestatic jaundice, elevated “liver” transaminase; in children – constipation, anorexia, gastritis.
Cardio-vascular system: palpitations, chest pain (1% or less).
From the nervous system: dizziness, headache, vertigo, drowsiness; in children – headache (in the treatment of otitis media), hyperkinesia, anxiety, neurosis, sleep disorders (1% or less).
From the urogenital system: vaginal candidiasis, nephritis (1% or less).
Allergic reactions: rash, photosensitivity, angioedema.
Other: fatigue; in children – conjunctivitis, pruritus, urticaria.
special instructions
In the case of missing receiving 1 dose missed dose should be taken as early as possible, and follow – with an interval of 24 hours.
It is necessary to observe a break in 2 h while the use of antacids.
After discontinuation of treatment hypersensitivity reactions in some patients may persist, which requires specific therapy under medical supervision.
Storage conditions
In a dry, dark place at a temperature from 15 to 25 C.
Keep out of the reach of children!.
Dosing and Administration
Inside for 1 hour before or 2 hours after eating 1 time per day. Adults and children older than 12 years with infections of the upper and lower respiratory tract – 0.5 g / day for 1 reception for 3 days (course dose – 1.5 g).
When the skin and soft tissue infections – 1 g / day for the first day after 1 reception, then at 0.5 g / day every day 2 through day 5 (course dose – 3 g).
In acute infections, urinary organs (uncomplicated urethritis or cervicitis) – Once 1 year
When Lyme disease (borreliosis) for the treatment of step I (erythema migrans) – 1 g on the first day and 0.5 g daily, from 2 to 5 day (course dose – 3 g).
In gastric ulcer and 12 duodenal ulcer associated with Helicobacter pylori – 1 g / day for 3 days in a combination therapy of H. pylori.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

STADA

There are no reviews yet.

Add your review